Eli Lilly & Co. vs Thermo Fisher Scientific, Inc.
LLY vs TMO — side-by-side comparison from reported financials. LLY leads 9, TMO leads 2 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Thermo Fisher Scientific, Inc.
TMO · Healthcare
$658.02+0.93%Mixed
| Metric | LLY | TMO |
|---|---|---|
| Price | $1 177.20 | $658.02 |
| Market cap | $1.05T | $243B |
| Revenue (TTM) | $79.7B | $46.3B |
| Revenue growth | +31.7% | -0.3% |
| Net margin | 33.5% | 15.0% |
| Free cash flow | $18.2B | $7.32B |
| Net cash (debt) | ($35.2B) | ($29.3B) |
| 1-year price return | +37.6% | +23.1% |
| P/E | 41.6 | 34.9 |
| P/E vs own history (cheap-side %) | 88% | 24% |
| Dividend yield | 0.52% | 0.27% |
| Return on equity | 93% | 13% |
| Altman Z-score | 7.10 | — |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 50,000 | 125,000 |
Full résumé-style profiles: LLY CV · TMO CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.